Seres Therapeutics
Update in progressMCRB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Seres Therapeutics, Inc. is a clinical‑stage biotherapeutics company focused on serious diseases. It is developing SER-155, an oral live biotherapeutic to decolonize GI pathogens, strengthen epithelial barrier, and modulate immunity to prevent bacterial bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplantation. It also pursues SER-603, a microbiome–targeted LBP, and SER-147 for metabolic and liver disease. Formerly Seres Health, renamed in 2015. Founded 2010, based in Cambridge, MA.
Company score
- Sentiment
- -0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.41
- Governance
- -0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Richard N. Kender B.S., M.B.A.
- Founded2010
- Employees66
- Websitewww.serestherapeutics.com
Identifiers
- ISINUS81750R2013
- FIGIBBG0099X6859
- CUSIP81750R102
- CIK0001609809